LACTOBACILLI FOR TREATING CARDIAC DYSFUNCTION
The use of a bacterium of the species Lactobacillus salivarius in the manufacture of a food product, dietary supplement or medicament for treating cardiac dysfunction, particularly myocardial infarction, congestive heart failure, dilated cardiomyopathy or inflammatory heart disease (including endocarditis, inflammatory cardiomegaly and myocarditis) is disclosed.
1 . A method for treating cardiac dysfunction in a mammal, wherein the method comprises administering a bacterium of the species Lactobacillus salivarius in an amount effective for treating cardiac dysfunction in a mammal in need thereof.
2 . The method of claim 1 , wherein the bacterium is of the species Lactobacillus salivarius strain 33 (Ls-33) (PTA-4800).
3 . The method of claim 1 , wherein the cardiac dysfunction is selected from congestive heart failure (CHF), coronary artery disease, myocardial infarction, inflammatory heart disease and dilated cardiomyopathy.
4 . The method of claim 3 , wherein the cardiac dysfunction is myocardial infarction.
5 . The method of claim 3 , wherein the cardiac dysfunction is dilated cardiomyopathy.
6 . The method of claim 3 , wherein the cardiac dysfunction is inflammatory heart disease.
7 . The method of claim 6 , wherein the inflammatory heart disease is selected from endocarditis, inflammatory cardiomegaly and myocarditis.
8 . The method of claim 1 , wherein the treatment of cardiac dysfunction comprises lowering of the Col I:Col III expression ratio.
9 . The method of claim 1 , wherein the mammal in need of the treatment ingests a high-fat diet.
10 . The method of claim 1 , wherein the mammal is a human.
11 . The method of claim 14 , wherein the food product, dietary supplement or medicament additionally comprises one or more further probiotics.
12 . The method of claim 14 , wherein the food product, dietary supplement or medicament additionally comprises a prebiotic.
13 . The method of claim 10 , wherein the prebiotic is polydextrose.
14 . The method of claim 1 , wherein the Lactobacillus salivarius is administered as a component of a food product, a dietary supplement or a pharmaceutical composition.
15 . The method of claim 14 , wherein the Lactobacillus salivarius is administered as a component of a food product.
16 . The method of claim 15 , wherein the Lactobacillus salivarius is administered as a component of a yogurt.
17 . The method of claim 14 , wherein the Lactobacillus salivarius is administered as a component of a dietary supplement.
18 . The method of claim 14 , wherein the Lactobacillus salivarius is administered as a component of a pharmaceutical composition.
19 . The method of claim 1 , wherein the Lactobacillus salivarius is administered at a dosage of from about 10 6 to about 10 12 CFU of bacteria/per dose.
20 . The method of claim 19 , wherein the Lactobacillus salivarius is administered at a dosage of about 10 9 to about 10 11 CFU of bacteria/dose.
21 . (canceled)